A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations.
about
Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray.What is the role of alternate splicing in antigen presentation by major histocompatibility complex class I molecules?Structural and functional characterization of a single-chain peptide-MHC molecule that modulates both naive and activated CD8+ T cellsPhotodynamic therapy of tumors can lead to development of systemic antigen-specific immune responseBeyond 51Cr release: New methods for assessing HIV-1-specific CD8+ T cell responses in peripheral blood and mucosal tissues.In vitro evolution of a T cell receptor with high affinity for peptide/MHC.Engineering and characterization of a stabilized alpha1/alpha2 module of the class I major histocompatibility complex product Ld.Streptococcus pneumoniae serotype 1 capsular polysaccharide induces CD8CD28 regulatory T lymphocytes by TCR crosslinking.In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.Patient immune response to tumors monitored using SCID mouse models.New methods for assessing T-cell responses.Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'.Soluble MOG35-55/I-A(b) dimers ameliorate experimental autoimmune encephalomyelitis by reducing encephalitogenic T cellsDevelopment and use of multimeric major histocompatibility complex molecules.MHC-Ig induces memory T cell formation in vivo and inhibits tumour growth.Interaction of streptavidin-based peptide-MHC oligomers (tetramers) with cell-surface TCRsT Cell Receptor Engineering and Analysis Using the Yeast Display Platform.Species Specific Differences of CD1d Oligomer Loading In Vitro.Making the most of major histocompatibility complex molecule multimers: applications in type 1 diabetes.The use of peptide-major-histocompatibility-complex multimers in type 1 diabetes mellitus.Role of 2CT cell receptor residues in the binding of self- and allo-major histocompatibility complexesModulation of MHC binding by lateral association of TCR and coreceptor.Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patientsAntigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes?Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells.Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling.Superactivation of an immune response triggered by oligomerized T cell epitopes.Analysis, Isolation, and Activation of Antigen-Specific CD4(+) and CD8(+) T Cells by Soluble MHC-Peptide Complexes.Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands.Tricks with tetramers: how to get the most from multimeric peptide-MHC.Epitope-specific tolerance induction with an engineered immunoglobulin.Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells.The potential of multimer technologies in type 1 diabetes prediction strategies.Peptide-MHC multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS vaccine development.Function and expression of CD1d and invariant natural killer T-cell receptor in the cotton rat (Sigmodon hispidus).Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity.Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells.Localization of soluble major histocompatibility class II-peptide complexes on T cell surface.
P2860
Q24815128-E589AB28-7C69-46EC-A330-373A161FA7EEQ27491004-306866DF-B954-4BB8-8170-BC76DC08C8C7Q27671616-D768DD29-CCAE-402C-B423-45DA27632E6CQ28744245-33129413-B7DB-4375-B9C0-2C909EE37954Q30332080-146447E0-3276-4A43-9441-C03A86B07FD3Q30861962-C78F08EB-669A-463E-9F7C-5A6C789C9D5FQ33248619-FB83E48E-BF92-4046-93A2-3061196D07B5Q33506614-21A60D46-CAE3-425E-B4F5-2979CE087A71Q33671654-74CC0B12-18AA-4DED-9EA6-2EF27A475813Q33943153-2B0A9A5F-06C4-4E11-928B-9E668857D9A4Q34076691-A3BCD303-0842-436C-926B-04D9829922A2Q34094070-AF01C72C-5FDE-4D04-985B-F45EAEB261D4Q34139182-E73C8B89-2418-4CFC-8FC5-06F5496E544CQ34450848-AEAA0997-FE39-4CB1-8550-78002A024680Q34550189-4522E952-0354-4E0D-ABD4-7AC14311F0CBQ34641196-72018D1E-A10C-4892-AC1F-511349CA731BQ35612835-0590C06D-67AB-4E18-8835-AC56FA35384DQ35659205-7B791163-66D5-4CD6-89B0-EA9584F017B7Q35850396-884DB658-CDD9-4CAC-A292-15ABACA4807BQ36010973-72030B99-EEDA-43D9-8249-2AF83C32A92EQ36228996-7529B920-B429-4181-AFA7-96FBF728D782Q36368381-FCF5385B-5826-4CDC-AA56-E447A1F4B0B7Q36379215-B0CFE501-1E84-4D02-ACFA-31795BD20267Q36383130-5CC372BC-5BB2-4540-BFA7-270CC07F9B18Q36498251-C7F4C403-105D-4347-BB4E-351546C9F22DQ36569023-93770D6F-46E5-4AFD-96FF-F46600079127Q36625004-BC652050-F1AD-4883-A376-664947815099Q36639793-7B1B019E-8720-4DB1-B4B6-6F97DAB1F467Q36828919-3CD2C07E-787A-492A-A44C-0ED3E9227706Q37054621-4B5FA8F1-8701-458F-867B-0D6D5770383DQ37242917-7546C2A6-7839-4C5B-9BC9-EE441C2A367DQ37363261-7F8F5937-8553-4B0B-BB7C-5DCF8EDB66CCQ37612708-783A416B-7495-4D07-A20F-7CE962933BA0Q37708824-1EF062F2-0245-4AB1-900F-16C2825C04A0Q37838895-3C789747-0E4F-4FD7-8AAB-6E7926F2D5D2Q38265356-45201ED5-68DB-4E9E-A3F4-B7F7EC8380C1Q38837176-43A61362-B6B6-4AF6-87F3-BC850FAC1C42Q39787217-9C726B72-7C94-4B64-A527-C2787F910B17Q39859712-4F42F860-9753-49F0-9A4B-A70624E8D339Q40861783-5F47A822-1938-4DC0-9777-F5A31669E410
P2860
A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
A soluble divalent class I maj ...... s at nanomolar concentrations.
@ast
A soluble divalent class I maj ...... s at nanomolar concentrations.
@en
type
label
A soluble divalent class I maj ...... s at nanomolar concentrations.
@ast
A soluble divalent class I maj ...... s at nanomolar concentrations.
@en
prefLabel
A soluble divalent class I maj ...... s at nanomolar concentrations.
@ast
A soluble divalent class I maj ...... s at nanomolar concentrations.
@en
P2093
P2860
P356
P1476
A soluble divalent class I maj ...... s at nanomolar concentrations.
@en
P2093
Catipović B
Dal Porto J
Johansen TE
Kozlowski S
Parfiit DJ
Schneck JP
P2860
P304
P356
10.1073/PNAS.90.14.6671
P407
P577
1993-07-01T00:00:00Z